No Matches Found
No Matches Found
No Matches Found
Changchun High-Tech Industry (Group) Co., Ltd.
Changchun High-Tech Stock Hits Day High with Strong 3.09% Intraday Gain
Changchun High-Tech Industry (Group) Co., Ltd. saw a significant rise on August 10, 2026, reaching an intraday high of CNY 83.73. Despite recent gains, the company has struggled over the past year, facing a notable decline in net sales and consecutive negative quarterly results. Its market capitalization stands at CNY 33,368 million.
Changchun High-Tech Stock Hits Day Low of CNY 72.18 Amid Price Pressure
Changchun High-Tech Industry (Group) Co., Ltd. saw a significant stock decline today, contrasting with broader market trends. Despite a slight recovery over the past week, the company has faced substantial long-term losses, with declining sales and negative results for seven consecutive quarters, raising concerns about its financial health.
Changchun High-Tech Stock Soars 5.48%, Hits Intraday High of CNY 71.17
Changchun High-Tech Industry (Group) Co., Ltd. saw a notable increase on July 10, 2026, despite facing significant long-term challenges. The company has experienced substantial declines in year-to-date and one-year performance, alongside ongoing financial difficulties, including a decrease in net sales and negative results over the past seven quarters.
Changchun High-Tech Stock Soars 5.51%, Hits Intraday High of CNY 70.73
Changchun High-Tech Industry (Group) Co., Ltd. saw a significant intraday increase on July 1, 2026, contrasting with the modest gain of the China Shanghai Composite. Despite recent short-term gains, the company has faced substantial long-term declines, reporting negative results for seven consecutive quarters and struggling with low financial metrics.
Changchun High-Tech Stock Soars 7.88%, Hits Intraday High of CNY 68.49
Changchun High-Tech Industry (Group) Co., Ltd. saw a notable stock increase today, contrasting with its significant long-term challenges, including a 31.3% decline over the past year and seven consecutive quarters of negative results. The company has a high dividend yield but struggles with negative return on equity and a complex financial situation.
Changchun High-Tech Stock Hits Day Low Amid Price Pressure at CNY 65.58
Changchun High-Tech Industry (Group) Co., Ltd. has faced significant challenges, with a notable stock decline and a 35.79% decrease over the past year. The company reported a net sales drop and negative results for seven consecutive quarters, reflecting ongoing struggles in profitability within the pharmaceuticals and biotechnology sector.
Changchun High-Tech Stock Hits Day Low of CNY 72.70 Amid Price Pressure
Changchun High-Tech Industry (Group) Co., Ltd. has faced significant stock declines, with a 9.43% drop over the past week and a 29.27% decrease over the past year. The company reports a net sales decline of 13.69% and a negative operating profit margin, reflecting ongoing financial challenges.
Changchun High-Tech Stock Hits Day Low Amid Price Pressure, Closes Down 4.67%
Changchun High-Tech Industry (Group) Co., Ltd. saw a notable stock decline today, reflecting ongoing challenges in the pharmaceuticals and biotechnology sector. The company has reported significant decreases in net sales and profits, alongside a troubling long-term performance, with substantial declines over the past year and three to five years.
Changchun High-Tech Stock Hits Day Low Amid Price Pressure, Closing at CNY 87.70
Changchun High-Tech Industry (Group) Co., Ltd. faced a significant stock decline today, contrasting with the broader market. The company reported a net sales drop and negative results for three consecutive quarters, alongside substantial decreases in profits. Its long-term performance has been underwhelming, with notable declines over the past year.
Changchun High-Tech Stock Soars 10% to Day High Amid Market Decline
Changchun High-Tech Industry (Group) Co., Ltd. saw a notable rise in its stock today, contrasting with a decline in the broader market. Despite recent gains, the company has faced challenges, including negative quarterly results and a long-term decline in operating profit, while operating in the pharmaceuticals and biotechnology sector.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
